Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients
A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of MP4OX Treatment, in Addition to Standard Treatment, in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock
Sponsor: Sangart
This PHASE2 trial investigates Acidosis, Lactic and Shock, Hemorrhagic and is currently completed. Sangart leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sangart
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Alberton, South Africa , Auckland, New Zealand , Beersheba, Israel , Berlin, Germany , Cali, Colombia , Cape Town, South Africa , Centurion, South Africa , Clichy, France , Cologne, Germany and 24 more locations